Dermatology

A long-term study of Celgene Corporation's apremilast showed that the oral selective inhibitor of phosphodiesterase 4 provides relief to adult patients with active psoriatic arthritis, as well as adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

AstraZeneca and Amgen tracked psoriasis patients taking brodalumab, ustekinumab (Stelara), or placebo, and the results showed brodalumab produced the greatest results in clearing skin.

Methotrexate injection treats patients with rheumatoid arthritis, polyarticular-course juvenile idiopathic arthritis, and psoriasis.

The FDA's Dermatologic and Ophthalmic Drugs Advisory Committee has recommended the approval of Novartis' first-in-class secukinumab therapy for moderate-to-severe plaque psoriasis.

Patients with moderate-to-severe psoriasis are more likely to have uncontrolled hypertension.

Early diagnosis is the key to successful management of psoriatic arthritis, and treatment of this inflammatory disease is largely dependent on which symptoms are predominant.

Patients who responded to brodalumab showed improvement in skin condition and joint swelling.

Recommendations for co-morbidities identified as an important step for the optimal care of patients.

Methotrexate, a traditional disease-modifying antirheumatic drug, may enhance the likelihood of therapeutic persistence with novel biologic agents.

Questionnaires given to patients with psoriasis predicted probable psoriatic arthritis in a significant number of patients.

Biologic agent golimumab effective over 5-year span in treating disease symptoms and improving quality of life.

Patients with psoriasis, psoriatic arthritis, or both conditions felt that their quality of life decreased if they experienced condition symptoms in more parts of their body.

Left untreated, psoriasis can lead to serious medical complications.

Left untreated, psoriasis can lead to serious medical complications.

Women in early pregnancy who eat foods to which children are commonly allergic may help reduce their child's risk for allergies and asthma, suggest the results of a recent study.

Luz Fonacier, MD, talks about the diagnosis and management of atopic dermatitis.

Secukinumab is the first therapy that selectively targets IL-17A in psoriasis to complete a Phase III trial.

Our round-up of the latest generic products.

A recent study compared the annual cost per treated patient for a health plan for patients taking etanercept, adalimumab, or infliximab.

The National Psoriasis Foundation Medical Board released a statement supporting the prohibition of biosimilar substitution pending the fulfillment of 7 key measures.

An assessment of costs and specialty drug use within 4 chronic conditions found specialty drugs contribute to overall costs for insurance plan members.

In the first reported clinical study of topical tofacitinib, investigators concluded that the Janus kinase inhibitor effectively reduced the clinical signs of psoriasis.

The cost of complex therapies is soaring, and the challenge is to deliver access to these medications in the most cost-effective and clinically appropriate site of service.